PORTLAND, ME -- (Marketwire) -- 07/19/12 -- (NASDAQ: ICCC) announced today that it received a Technical Section Complete Letter from the FDA relating to its Effectiveness Technical Section submission for ®, its Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. This FDA letter confirms that the regulatory requirements to demonstrate the effectiveness of ® have been met. Commercial sales of ® cannot begin until the New Animal Drug Application (NADA) is approved by the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA)."Ach [...]


read original news on firmenpresse.de